- Home
- |
- Contact
- |
- Pharmacovigilance
- |
Welcome to
Chiesi group
Parma (Italy), September 23, 2021 – Chiesi, the international research-focused pharmaceutical and healthcare Group (Chiesi Group), has obtained an A rating for its high capacity to manage environmental, social, and governance (ESG) risks and opportunities from Cerved Rating Agency. With an overall ESG score of 73.7, Chiesi is among the best performing companies in the Healthcare Products sector, according to the Italian rating agency specialised in the ESG performances of companies.
The rating report highlights that Chiesi successfully integrates ESG factors into its business processes. The company’s certification as the largest B Corp certified pharmaceutical company globally and the change in its legal status into a Benefit Corporation in several jurisdictions testify to the profound sustainable transformation of the business and the sincerity of Chiesi’s shared value approach, Cerved Rating Agency said. Chiesi Group particularly stands out for its performance in environmental and social dimensions. The report underlines the development of a carbon-minimal inhaler, the carbon neutrality target by 2035, as well as the adoption of a life cycle assessment methodology in product development, which also includes a patient-centric R&D methodology, as hallmarks of the Group’s sustainability work.
Chiesi also scores high on employee well-being and workplace satisfaction. Cerved Rating Agency particularly commends the majority-female R&D workforce, training hours administered per capita, and the level of employee retention.
“We’re proud to receive such a positive rating from Cerved, confirming that our ‘Actions Over Words’ approach is bearing fruit.” said Maria Paola Chiesi, Shared Value & Sustainability Head of Chiesi Group. “The recognition of our initiatives, many of which are without precedent among large pharmaceutical companies, from a renowned and independent ESG body such as Cerved Rating Agency is key for us in validating best practice. They also provide the necessary constructive input that allows us to continue on our path toward becoming a truly sustainable pharmaceutical company, in line with our creed of ‘Making the world feel better’.”
Chiesi continues to strive for a better understanding of its impact on society and the environment. It believes that common measurement indicators are key to ensure that companies’ impacts are transparently and comparably documented, motivating businesses to further improve their ESG performances. To this end, the Cerved ESG rating, alongside previously implemented tools such as the B Impact Assessment, serves as an indicator of Chiesi’s ability to integrate the concept of shared value into its business model.
About Chiesi Group
Based in Parma, Italy, Chiesi is an international research-focused pharmaceuticals and healthcare group with over 85 years’ experience, operating in 30 countries with more than 6,000 employees (Chiesi Group). To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, the Group researches, develops and markets innovative therapeutic solutions in its three focus areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support specialty care and consumer-facing self-care). The Group’s Research and Development centre is based in Parma and works alongside 6 other important research and development hubs in France, the U.S., Canada, China, the UK, and Sweden to pursue its pre-clinical, clinical, and regulatory programmes. In 2018 Chiesi changed its legal status to Benefit Corporation, according to the law in Italy, USA and, more recently, in France, by incorporating common benefit objectives into its bylaws, to generate value for its business, for the society and the environment. Since 2019, Chiesi has been the world’s largest B Corp certified pharmaceutical group. B Corps are global leaders convinced to leverage business as a force for good. Moreover, as a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to report annually in a transparent way about its progress in achieving the common benefits objectives it has set forward. The Group is committed to becoming carbon neutral by the end of 2035.
For further information: www.chiesi.com
About Cerved Rating Agency
Cerved Rating Agency is the Italian rating agency specialized in the assessment of the creditworthiness of Italian non-financial companies and their debt securities: it issues solicited and unsolicited credit ratings.
CRA is a credit rating agency registered with ESMA according to Regulation EC 1060/2009. As External Credit Assessment Institution (ECAI) under Regulation EC n. 575/2013 it provides more than 25,000 ratings to Italian institutions that use them for regulatory purposes.
Cerved Rating Agency, through its ESG Solutions, issues also sustainability assessments on financial and non-financial corporates to companies that adopt sustainability in their business model and to investors who operate according to the principles of responsible investment. The core business is focused on offering sustainability ratings based on the analysis and measurement of ESG factors published by companies in their sustainability reports and non-financial statements. Cerved Rating Agency adopts a rigorous approach in the analysis of ESG factors by applying a standardized proprietary metric. The rating methodology is developed on the basis of publication standards of ESG data and information recommended by the Global Reporting Initiative. The use of machine learning and big data analytics technologies make it possible to integrate the ESG offer with innovative and high added value services.
Media contacts:
Alessio Pappagallo
Press Office Manager
Phone +39 339 589 483
Email a.pappagallo@chiesi.com
